As previously reported, Leerink analyst David Larsen upgraded AmerisourceBergen (ABC) to Outperform from Market Perform and raised his price target on the shares to $95 from $75. The analyst believes the odds of the Walgreens Boots Alliance (WBA)/Rite Aid (RAD) transaction going through have "increased substantially," and believes that the long-term partnership with Walgreens Boots Alliance will act as a positive driver for volumes. Long-term, Larsen believes that AmerisourceBergen will continue to benefit from growth in specialty, biosimilars, and generic launches, while recent commentary seems to indicate that generic deflation trends are moderating.